Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4;15(1):32.
doi: 10.1038/s41408-025-01222-y.

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

James A Davis  1 , Jordan Snyder  2 , Mikhaila Rice  3 , Donald C Moore  4 , Christopher Cahoon  5 , Kelley Julian  5 , Charlotte B Wagner  5 , Katelynn Granger  6 , Kimberly M Green  6 , Shebli Atrash  4 , Hailey Hill  4 , Jessica McElwee  4 , Grace Elsey  4 , Jack Khouri  3 , Joslyn Rudoni  3 , Zahra Mahmoudjafari  2 , Victoria R Nachar  7
Affiliations

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

James A Davis et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interest: JAD: consultancy: Janssen. MR: consultancy: Janssen. ZM: consultancy: Janssen, Pfizer, Sanofi. SA: Research Funding: GSK, AMGEN, Karyopharm; Honoraria: Janssen. KJ: consultancy: Pfizer, Janssen (J&J), and BioLineRx. CBW: consultancy: Pfizer. JK: honoraria GPCR Therapeutics, Legend Biotech; Consultancy: Janssen. Ethics approval and consent to participate: All centers obtained institutional review board approval, which granted a waiver of patient consent, and the study was conducted in accordance with the Declaration of Helsinki. All centers obtained institutional review board approval, reference # Pro00122996.

Figures

Fig. 1
Fig. 1. CRS management strategies and efficacy outcomes.
A Sankey diagram of grade 1 CRS incidence and management strategies. B Sankey diagram of grade 2 CRS incidence and management strategies. C Best ORR stratified by CRS management strategy. D PFS stratified by CRS management strategy.
See this image and copyright information in PMC

References

    1. Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018;24:705–6. - PubMed
    1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38. - PubMed
    1. Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol. 2024;15:1-16. - PMC - PubMed
    1. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143:1565–75. - PubMed
    1. Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk N, Leleu X, Gallego Perez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205–e16. - PubMed

LinkOut - more resources